Keytruda® (pembrolizumab) – New indication
June 12, 2018 - Merck announced the FDA approval of Keytruda (pembrolizumab) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (combined positive score [CPS] ≥ 1) as determined by an FDA-approved test.
Top